Valuation: Cyclopharm Limited

Market Cap 68.71M 48.52M 41.97M 39.2M 35.96M 67.63M 4.62B 460M 181M 2.31B 182M 178M 7.65B P/E 2026 *
-3.7x
P/E 2027 * -7.93x
Enterprise Value 68.71M 48.52M 41.97M 39.2M 35.96M 67.63M 4.62B 460M 181M 2.31B 182M 178M 7.65B EV / Sales 2026 *
1.88x
EV / Sales 2027 * 1.49x
Free-Float
58.05%
Yield 2026 *
-
Yield 2027 * -
1 day-1.80%
1 week-6.84%
Current month-6.84%
1 month+18.48%
3 months-26.85%
6 months-44.67%
Current year-44.39%
1 week 0.54
Extreme 0.54
0.6
1 month 0.48
Extreme 0.485
0.66
Current year 0.45
Extreme 0.45
1.29
1 year 0.45
Extreme 0.45
1.29
3 years 0.45
Extreme 0.45
3.15
5 years 0.45
Extreme 0.45
3.15
10 years 0.45
Extreme 0.45
3.45
Manager TitleAgeSince
Chief Executive Officer 60 21/10/2009
Director of Finance/CFO - 26/02/2024
Chief Operating Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 60 03/06/2008
Director/Board Member 65 10/08/2021
Director/Board Member - 01/09/2022
Date Insider Type Main position Quantity % Market Cap.
3/12/26 A Buy

Chief Executive Officer

10,526 0.0087%
2/26/25 A Buy

Director

13,500 0.0121%
2/26/25 A Buy

Chairman

8,874 0.0080%
Change 5-day change 1-year change 3-year change Capi.($)
-1.80%-6.84%-44.39%-76.51% 48.52M
+2.41%+3.43%+30.62%+7.65% 220B
+2.39%+5.02%+3.16%-19.90% 144B
+1.36%+7.21%-19.37%+22.50% 134B
+0.02%+5.52%-52.11%-2.80% 71.46B
+0.45%+4.24%+15.13%+12.37% 51.71B
+1.05%+7.19%-14.42%-19.02% 50.84B
+3.28%+5.49%+28.07%+15.38% 41.23B
+1.79%+7.83%+46.35%+40.43% 39.95B
+2.08%+5.51%+0.94%-5.05% 32.42B
Average +1.30%+4.31%-0.60%-2.49% 78.51B
Weighted average by Cap. +1.79%+5.17%+5.03%+4.31%

Financials

2026 *2027 *
Net sales 36.6M 25.85M 22.36M 20.88M 19.15M 36.03M 2.46B 245M 96.15M 1.23B 97.07M 94.94M 4.08B 46.2M 32.63M 28.22M 26.36M 24.18M 45.48M 3.11B 309M 121M 1.56B 123M 120M 5.15B
Net income -18.9M -13.35M -11.55M -10.78M -9.89M -18.6M -1.27B -127M -49.65M -637M -50.13M -49.03M -2.11B -9.9M -6.99M -6.05M -5.65M -5.18M -9.75M -665M -66.27M -26.01M -334M -26.26M -25.68M -1.1B
Net Debt - -
Logo Cyclopharm Limited
Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its Technegas product is a broad-spectrum diagnostic lung imaging technology for visualization of pulmonary ventilation and lung function. It includes the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. Company distributes its products in approximately 65 countries.
Employees
109
Date Price Change Volume
07/08/26 A$0.5450 -1.80% 25,968
06/08/26 A$0.5550 +1.83% 7,603
05/08/26 A$0.5450 -2.68% 86,597
04/08/26 A$0.5600 +0.90% 25,320
03/08/26 A$0.5550 -5.13% 134,675
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3849USD
Average target price
0.6940USD
Spread / Average Target
+80.30%

Quarterly revenue - Rate of surprise